Table 5.
Current treatment information for recently diagnosed and established MDS patients, by IPSS risk score*
| IPSS Low/Int-1 |
IPSS Int-2/High |
|||||||||||||
| Recently diagnosed patients, % (95% CI) (N = 432) | Established patients, % per survey (N = 4514) |
Recently diagnosed patients, % (95% CI) (N = 198) | Established patients, % per survey (N = 4514) |
|||||||||||
| Treatment | Survey 1 (n = 614) | Survey 2 (n = 664) | Survey 3 (n = 816) | Survey 4 (n = 789) | Survey 5 (n = 804) | Survey 6 (n = 827) | Survey 1 (n = 614) | Survey 2 (n = 664) | Survey 3 (n = 816) | Survey 4 (n = 789) | Survey 5 (n = 804) | Survey 6 (n = 827) | ||
| Monitoring† | 24 (20 to 28) | 19 | 15 | 16 | 19 | 17 | 18 | 5 (2 to 7) | 12 | 6 | 9 | 9 | 5 | 10 |
| Supportive care‡, with or without other treatments | 70 (66 to 74) | 77 | 82 | 80 | 74 | 78 | 77 | 83 (78 to 89) | 84 | 85 | 80 | 68 | 88 | 79 |
| Transfusion§ | 17 (14 to 21) | 31 | 24 | 24 | 3 | 25 | 18 | 54 (47 to 61) | 70 | 52 | 50 | 3 | 66 | 48 |
| ESA | 59 (54 to 64) | 58 | 63 | 62 | 64 | 65 | 64 | 58 (51 to 65) | 48 | 63 | 57 | 54 | 55 | 56 |
| G(M)-CSF | 5 (3 to 7) | 7 | 6 | 8 | 5 | 8 | 7 | 19 (14 to 25) | 20 | 21 | 15 | 21 | 21 | 28 |
| Vitamins and supplements | 22 (18 to 26) | 10 | 22 | 21 | 20 | 23 | 20 | 16 (11 to 21) | 4 | 19 | 17 | 21 | 17 | 15 |
| Supportive care‡ without other treatments | 53 (49 to 58) | 58 | 67 | 61 | 60 | 60 | 61 | 27 (21 to 33) | 37 | 49 | 33 | 24 | 31 | 33 |
| Transfusion§ | 2 (1 to 3) | 4 | 5 | 4 | 3 | 2 | 3 | 4 (1 to 6) | 9 | 7 | 5 | 3 | 9 | 4 |
| ESA | 27 (23 to 31) | 29 | 32 | 29 | 38 | 28 | 34 | 6 (3 to 9) | 5 | 9 | 10 | 11 | 6 | 7 |
| G(M)-CSF | 0 (0 to 1) | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Vitamins and supplements | 4 (2 to 6) | 4 | 5 | 5 | 3 | 3 | 4 | 0 | 1 | 4 | 0 | 4 | 2 | 2 |
| Other treatments‖, with or without supportive care | 22 (18 to 26) | 23 | 18 | 23 | 22 | 23 | 21 | 69 (62 to 75) | 51 | 45 | 59 | 66 | 64 | 57 |
| Other treatments‖ without supportive care | 6 (4 to 9) | 6 | 4 | 5 | 8 | 5 | 5 | 12 (8 to 17) | 4 | 9 | 11 | 22 | 8 | 11 |
The total “n” listed at the heading of each established patients survey column includes recently diagnosed (ie, diagnosed in the previous 2 months) and established patients for whom this information was collected in that survey. Results for recently diagnosed patients were combined from across all six surveys and reported along with 95% CIs. Excludes 40 recently diagnosed patients and 133 established patients with missing values for IPSS risk score. MDS = myelodysplastic syndrome; IPSS = International Prognostic Scoring System; Low/Int-1 = low and intermediate-1 risk classification; Int-2/High = intermediate-2 and high risk classification; CI = confidence interval; ESA = erythropoiesis-stimulating agents; G(M)-CSF = granulocyte–macrophage colony-stimulating factor.
Patients who were being monitored without receiving any form of therapy (“watch and wait” patients).
Supportive care includes growth factors (erythropoietin, darbepoetin, G-CSF, GM-CSF, pegfilgrastim), vitamins and supplements, red blood cell transfusions, platelet transfusions, glucocorticoids, cytokines (IL11), immunoglobulins and bisphosphonates.
Red blood cell and/or platelet transfusions.
Other treatments include 6-thioguanine, alemtuzumab, all-trans-retonic acid, amifostine trihydrate, anagrelide, androgens, arsenic trioxide, azacitidine, bortezomib, busulfan, CellCept, cladribine, cyclophosphamide, cyclosporine, cytarabine, daunorubicin, decitabine, etoposide, fludarabine, gemtuzumab, hydroxyurea, idarubicin, imatinib mesylate, lenalidomide, leuprolide, melphalan, methotrexate, mitoxantrone, pentostatin, rituximab, strontium 89, thalidomide, tipifarnib, topotecan, and other chemotherapy, biologics, immunotherapy, and DNA therapy.